OAT3 Inhibitors
2 drugsAbout OAT3
Organic anion transporter 3 (OAT3) is a membrane transport protein that facilitates the movement of molecules across cell membranes, influencing the concentration of various compounds within the body.
OAT3's role in regulating compound concentrations makes it a potential drug target, influencing the pharmacokinetics and pharmacodynamics of other medications. Currently, there is no genetic evidence directly linking OAT3 to specific diseases.
OAT3 is targeted by two FDA-approved small molecule drugs: PROBALAN (LANNETT) and ORLYNVAH (ITERUM THERAP), both approved for other therapeutic areas beyond common indications.
Top OAT3 Drugs
The competitive landscape consists of two companies, LANNETT and ITERUM THERAP, with approved drugs targeting OAT3.
Low market concentration suggests relatively low barriers to entry for new competitors targeting OAT3.
OAT3 Drug Modality Landscape
Modalities
Routes of Administration
OAT3 is amenable to small molecule drugs, with oral options available for convenient dosing.
The exclusive use of small molecules indicates a whitespace opportunity for alternative modalities like antibodies or biologics.
OAT3 Clinical Trials 46 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on OAT3. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 29 | 24 | 1 | 4 | 96% |
| Phase 2 | 8 | 5 | 0 | 3 | 100% |
| Phase 3 | 7 | 5 | 0 | 2 | 100% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
OAT3 Drug Approval Timeline (1976 - 2024)
The approval timeline for OAT3 drugs spans 49 years, with the first drug approved in 1976 and the most recent in 2024.
The long approval span indicates renewed interest in OAT3 as a target, suggesting potential for further drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 36 (21 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on OAT3. A trial counts if an approved drug acting on OAT3 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.